IONIS PHARMACEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
IONS$39.42+1.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
| ITEM 5. | OTHER INFORMATION |
|---|
Trading Plans
During the quarter ended June 30, 2024, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.
| * | Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. |
|---|
| ** | “Non-Rule 10b5-1 trading arrangement” as defined in item 408(c) of Regulation S-K under the Exchange Act. |
|---|
| Action | Date | Trading Arrangement | Total Shares to Be Sold | Expiration Date | |
|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5-1** | ||||
| Brett P. Monia Chief Executive Officer | Termination | June 26, 2024 | X | 54,442 | Upon the execution of all instructions provided in the plan |
| Richard S. Geary EVP, Chief Development Officer | Adoption | April 8, 2024 | X | 241,732 | The earlier to occur of (i) July 7, 2025, and (ii) Upon the execution of all instructions provided in the plan |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.